Monopar Therapeutics Inc. (NASDAQ: MNPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 43.72% | Shs Outstand | 6.70M | Perf Week | -12.51% |
| Market Cap | 646.26M | Forward P/E | - | EPS next Y | -2.46 | Insider Trans | -0.49% | Shs Float | 4.16M | Perf Month | -22.10% |
| Enterprise Value | 593.61M | PEG | 1.44 | EPS next Q | -0.86 | Inst Own | - | Short Float | 20.48% | Perf Quarter | 42.98% |
| Income | -14.02M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.88 | Perf Half Y | 64.43% |
| Sales | 0.00 | P/B | 6.30 | EPS next Y | 14.97% | ROA | -13.22% | Short Interest | 852.42K | Perf YTD | 47.73% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -13.08% | 52W High | 124.82 -22.71% | Perf Year | 44.76% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -16.89% | 52W Low | 50.07 92.67% | Perf 3Y | 3042.35% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.15% 5.29% | Perf 5Y | 247.01% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -59.56% | Oper. Margin | 0.00% | ATR (14) | 5.93 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 33.56 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 32.48 | Recom | 2.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 33.56 | EPS Q/Q | -77.14% | SMA20 | -12.76% | Beta | 1.43 | Target Price | 126.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -13.48% | Rel Volume | 1.71 | Prev Close | 102.70 |
| Employees | 22 | LT Debt/Eq | - | Earnings | Nov 12 | SMA200 | 26.87% | Avg Volume | 223.56K | Price | 96.47 |
| IPO Date | Dec 19, 2019 | Option/Short | No / Yes | EPS/Sales Surpr. | 3.64% - | Net Debt/EBITDA | 2.85 | Volume | 382,774 | Change | -6.07% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-11-26 | Reiterated | Barclays | Overweight | $128 → $145 |
| Aug-17-26 | Reiterated | Morgan Stanley | $115 → $130 | |
| Aug-13-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | $119 |
| Aug-13-26 | Reiterated | Barclays | Overweight | $125 → $128 |
| Aug-12-26 | Reiterated | BTIG | Buy | $117 → $133 |
| Jul-23-26 | Reiterated | UBS | $105 → $125 | |
| Jul-22-26 | Reiterated | HC Wainwright & Co. | Buy | $105 → $125 |
| Jun-30-26 | Reiterated | BTIG | Buy | $104 → $117 |
| Jun-29-26 | Reiterated | UBS | $37 → $105 | |
| Jun-02-26 | Reiterated | Piper Sandler | Overweight | $95 → $105 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 6,800 | 3 | 3 | — | — | — | — | — | — | |
| Research and Development | 9,904 | 13 | 6 | — | — | — | — | — | — | |
| Other Operating Expense | -16,687 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -17 | -16 | -9 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 1 | 0 | — | — | — | — | — | — | |
| Net Income Before Taxes | -14 | -16 | -8 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -14 | -16 | -8 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -14 | -16 | -8 | — | — | — | — | — | — | |
| Net Income | -14 | -16 | -8 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.85 | -1.36 | -0.58 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.85 | -1.36 | -0.58 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.85 | -1.36 | -0.58 | — | — | — | — | — | — | |
| EBITDA | -14 | -16 | -8 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 7 | 11 | 15 | — | — | — | — | — | — | |
| Market Capitalization | 457 | 242 | 26 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director | Aug 26 '26 | Option Exercise | 22.04 | 8,180 | 180,280 | 8,140 | Aug 28 |
| Tsuchimoto Kim R | Director | Aug 26 '26 | Sale | 111.39 | 8,180 | 911,134 | 0 | Aug 28 |
| Anderson Raymond | Director | Aug 25 '26 | Option Exercise | 30.00 | 6,284 | 188,520 | 8,515 | Aug 28 |
| Anderson Raymond | Director | Aug 25 '26 | Sale | 111.88 | 6,284 | 703,024 | 5,373 | Aug 28 |
| RIOUX PATRICE | other: Acting Chief Medical Officer | Aug 26 '26 | Option Exercise | 0.01 | 2,760 | 14 | 5,066 | Aug 27 |
| RIOUX PATRICE | other: Acting Chief Medical Officer | Aug 26 '26 | Sale | 111.26 | 1 | 111 | 5,065 | Aug 27 |
| Vu Quan Anh | Chief Financial Officer | Jun 30 '26 | Option Exercise | 0.00 | 1,228 | 0 | 2,728 | Jul 02 |
| Robinson Chandler | Chief Executive Officer | Jun 30 '26 | Option Exercise | 0.00 | 12,873 | 0 | 103,351 | Jul 02 |
| Cittadine Andrew | Chief Operating Officer | Jun 30 '26 | Option Exercise | 0.00 | 5,254 | 0 | 57,923 | Jul 02 |
| Robinson Chandler | Chief Executive Officer | Mar 31 '26 | Option Exercise | 0.00 | 6,732 | 0 | 92,450 | Apr 02 |
| Cittadine Andrew | Chief Operating Officer | Mar 31 '26 | Option Exercise | 0.00 | 3,514 | 0 | 54,240 | Apr 02 |
| Robinson Chandler | Chief Executive Officer | Dec 31 '25 | Option Exercise | 0.00 | 8,724 | 0 | 88,276 | Jan 05 |
| Cittadine Andrew | Chief Operating Officer | Dec 31 '25 | Option Exercise | 0.00 | 4,326 | 0 | 52,615 | Jan 05 |
| Vu Quan Anh | Chief Financial Officer | Dec 26 '25 | Buy | 69.95 | 1,500 | 104,925 | 1,500 | Dec 29 |
| KLAUSNER ARTHUR J | Director | Dec 18 '25 | Sale | 67.15 | 5,121 | 343,889 | 8,762 | Dec 19 |